Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells

Circulation

Volumn 113, Issue 5, 2006, Pages 691-700

  Kawakami, Akio ^a   Aikawa, Masanori ^a   Libby, Peter ^a   Alcaide, Pilar ^a   Luscinskas, Francis W ^a   Sacks, Frank M ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Apolipoproteins; Atherosclerosis; Cell adhesion molecules; Leukocytes

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; BETA1 INTEGRIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PROTEIN KINASE C ALPHA; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; VERY LOW DENSITY LIPOPROTEIN; APOLIPOPROTEIN C; LIPOPROTEIN; RHOA PROTEIN, HUMAN;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL ADHESION; CELL CULTURE; CELL LINE; CONTROLLED STUDY; CULTURE MEDIUM; DIET RESTRICTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MONOCYTE; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; SHEAR FLOW; VASCULAR ENDOTHELIUM; VOLUNTEER; BLOOD; CHEMISTRY; CYTOLOGY; METABOLISM; PHYSIOLOGY;

ANTIGENS, CD29; APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; APOLIPOPROTEINS C; ATHEROSCLEROSIS; CELL ADHESION; ENDOTHELIUM, VASCULAR; HUMANS; LIPOPROTEINS; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MONOCYTES; PROTEIN KINASE C-ALPHA; RHOA GTP-BINDING PROTEIN;

EID: 33644866843     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.591743     Document Type: Article

References (29)

1. Jong MC, Hofker MH, Havekes LM. Role of apoCs in lipoprotein metabolism: functional differences between apoC1, apoC2, and apoC3. Arterioscler Thromb Vasc Biol. 1999;19:472-484.
2. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoprotein C-III. J Clin Invest. 1985;75:384-390.
3. Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol. 1995;15:963-971.
4. Cohn JS, Patterson BW, Uffelman KD, Davignon J, Steiner G. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J Clin Endocrinol Metab. 2004;89:3949-3955.
5. Alaupovic P. Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Methods Enzymol. 1996;263:32-60.
6. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol. 1997;17:715-722.
7. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MT, Pfeffer MA, Braunwald E. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000;102:1886-1892.
8. Lee SJ, Campos H, Moye LA, Sacks FM. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol. 2003;23:853-858.
9. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 1997;30:1212-1217.
10. Rezaie-Majd A, Prager GW, Bucek RA, Schernthaner GH, Maca T, Kress H-G, Valent P, Binder BR, Minar E, Baghestanian M. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2003;23:397-403.
11. Kawakami A, Tanaka A, Nakajima K, Shimokado K, Yoshida M. Atorvastatin attenuates remnant lipoprotein-induced monocyte adhesion to vascular endothelium under flow conditions. Circ Res. 2002;91:263-271.
12. Marcoux C, Tremblay M, Nakajima K, Davignon T, Cohn TS. Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients. J Lipid Res. 1999;40:636-647.
13. Bukberg PR, Le NA, Ginsberg HN, Gibson JC, Rubinstein A, Brown WV. Evidence for non-equilibrating pools of apolipoprotein C-III in plasma lipoproteins. J Lipid Res. 1985;26:1047-1057.
14. Breyer ED, Le NA, Li X, Martinson D, Brown WV. Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size. J Lipid Res. 1999;40:1875-1882.
15. Lim YC, Wakelin MW, Henault L, Goetz DT, Yednock T, Cabanas C, Sanchez-Madrid F, Lichtman AH, Luscinskas FW. α4β1-integrin activation is necessary for high-efficiency T-cell subset interactions with VCAM-1 under flow. Microcirculation. 2000;7:201-214.
16. Yoshida M, Sawada T, Ishii H, Gerszten RE, Rosenzweig A, Gimbrone MA Jr, Yasukochi Y, Numano F. HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol. 2001;21:1165-1171.
17. Luscinskas FW, Kansas GS, Ding H, Pizcueta P, Schleiffenbaum BE, Tedder TF, Gimbrone MA Jr. Monocyte rolling, arrest and spreading on IL-4-activated vascular endothelium under flow is mediated via sequential action of L-selectin, β1-integrins, and β2-integrins. J Cell Biol. 1994;125:1417-1427.
18. Huo Y, Hafezi-Moghadam A, Ley K. Role of vascular cell adhesion molecule-1 and fibronectin connecting segment-1 in monocyte rolling and adhesion on early atherosclerotic lesions. Circ Res. 2000;87:153-159.
19. Campos H, Perlov D, Khoo C, Sacks FM. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. J Lipid Res. 2001;42:1239-1249.
20. Gibson JC, Rubinstein A, Bukberg PR, Brown WV. Apolipoprotein E-enriched lipoprotein subclasses in normolipidemic subjects. J Lipid Res. 1983;24:886-898.
21. Yu T, Morita I, Shimokado K, Iwai T, Yoshida M. Amlodipine modulates THP-1 cell adhesion to vascular endothelium via inhibition of protein kinase C signal transduction. Hypertension. 2003;42:329-334.
22. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47:859-866.
23. Rask-Madsen C, King GL. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol. 2005;25:487-496.
24. Holinstat M, Mehta D, Kozasa T, Minshall RD, Malik AB. Protein kinase Cα-induced p115RhoGEF phosphorylation signals endothelial cytoskeletal rearrangement. J Biol Chem. 2003;278:28793-28798.
25. 2+-dependent β cell death in type 1 diabetes. Proc Natl Acad Sci U S A. 2004;101:10090-10094.
26. Moudry R, Spycher MO, Doran JE. Reconstituted high density lipoprotein modulates adherence of polymorphonuclear leukocytes to human endothelial cells. Shock. 1997;7:175-181.
27. Barter PJ, Nicholls S, Rye K-A, Anantharamaiah GM, Navab M, Fogelman AM. Anti-inflammatory properties of HDL. Circ Res. 2004;95:764-772.
28. Blankenhom D, Alaupovic P, Wickham E, Chin H, Azen S. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation. 1990;81:470-476.
29. Onat A, Hergenc G, Sansoy V, Fobker M, Ceyhan K, Toprak S, Assmann G. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis. 2003;168:81-89.